(Q47561677)

4 February 2018

title

Copper-64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma (English)

1 reference

4 February 2018

16

Guido Marcucci

1 reference

4 February 2018

Enrico Caserta

1

1 reference

4 February 2018

Junie Chea

2

1 reference

4 February 2018

Megan Minnix

3

1 reference

4 February 2018

Domenico Viola

4

1 reference

4 February 2018

Steven Vonderfecht

5

1 reference

4 February 2018

Paul Yazaki

6

1 reference

4 February 2018

Desiree Crow

7

1 reference

4 February 2018

Jihane Khalife

8

1 reference

4 February 2018

James F Sanchez

9

1 reference

4 February 2018

Joycelynne M Palmer

10

1 reference

4 February 2018

Susanta Hui

11

1 reference

4 February 2018

Nadia Carlesso

12

1 reference

4 February 2018

Jonathan Keats

13

1 reference

4 February 2018

Young Kim

14

1 reference

4 February 2018

Ralf Buettner

15

1 reference

4 February 2018

Steven Rosen

17

1 reference

4 February 2018

John Shively

18

1 reference

4 February 2018

David Colcher

19

1 reference

4 February 2018

Amrita Krishnan

20

1 reference

4 February 2018

Flavia Pichiorri

21

1 reference

4 February 2018

language of work or name

English

0 references

publication date

4 January 2018

1 reference

4 February 2018

published in

Blood

1 reference

4 February 2018

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

The Critical Role of Imaging in the Management of Multiple Myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

New investigational drugs with single-agent activity in multiple myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Minimal residual disease in multiple myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Radioimmunodetection of amyloid deposits in patients with AL amyloidosis

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

The treatment of relapsed and refractory multiple myeloma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5814935

Clinically relevant end points and new drug approvals for myeloma

1 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29301755

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2017-09-807263

1 reference

4 February 2018

PMC publication ID

5814935

0 references

1 reference

4 February 2018